The Nantes-based company has just completed a third round of financing, raising €2.5 million to fund a clinical trial of its novel system for recovering blood lost by patients during hemorrhagic surgery. The only such solution to preserve platelets. i-SEP hopes to obtain CE marking by the end of 2020 to launch its pre-marketing.
i-SEP is getting closer to its goal: launch its unique intraoperative cell salvage technology (IOCS). This consists in recovering the blood lost from a patient during hemorrhagic surgery in the operating theatre, treating the blood and transfusing it back into the patient. This practice concerns about 4 million people per year in Europe and the United States. To this end, the Nantes-based company has just completed its third round of funding at €2.5 million with its historical shareholders, including Go Capital Amorçage, a pool of business angels and family offices brought together by the Gwenneg crowdfunding platform. i-SEP uses unique tangential filtration technology, “which ensures the preservation of platelets in a functional state, unlike the centrifugation processes used by our competitors”, summarizes Sylvain Picot, Chairman and co-founder of the company with Francis Gadrat and Bertrand Chastenet. The trio will retain a blocking minority after the transaction.
The company is finalizing its pre-clinical trials. Its technology has received in-vitro validation from the French National Blood Bank (EFS) and in-vivo validation from the Oniris National Veterinary School in Nantes. These funds will be used to refine the third generation of prototypes to launch a multi-centre clinical trial in Bordeaux, Rennes and Paris in the first half of 2020. “The aim of this study is to confirm the results in surgical procedures with a high risk of bleeding, such as cardiac or orthopedic procedures” explains Patricia Forest-Villegas, CSO, Regulatory Affairs & Quality Manager at i-SEP.
This latest generation is characterized by sleek ergonomics, compactness and mobility, a start-up system and a filtration kit that is easy to set up with a clip-on template. As Sylvain Picot explains, “This keeps things simple which is to the liking of the physicians and removes one of the major obstacles to the widespread use of intraoperative autotransfusion”. This decisive step will see the solution overcome regulatory barriers and obtain CE marking by the end of 2020.
Date of creation : 2015
Chairman : Sylvain Picot
Amount : €2,5 million
Number of employees: 12 personnes
Sector : medtech